Intercept Pharmaceuticals is not commenting on reports that the company did not appropriately disclose safety information about its lead drug candidate obeticholic acid (OCA), but Intercept released a set of e-mail messages on 22 May that show the company knew about OCA's impacts on cholesterol in the investigator-sponsored FLINT trial as early as 6 January.
OCA's effects on lipid levels in nonalcoholic steatohepatitis (NASH) patients were not unexpected, since diabetes and cardiovascular disease are common...